BIOM-02. IDENTIFYING MGMT ALTERATIONS AS BIOMARKERS OF SURVIVAL IN LUNG ADENOCARCINOMA WITH BRAIN METASTASES

EGFR-mutant lung adenocarcinomas (EGFRm-LUAD) have a higher risk of developing brain metastases (BM) compared to non-EGFR-mutant tumors. BM development has significant prognostic impact and leads to poorer patient survival. MGMT promoter methylation is known to determine response to therapy in other...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Mamatjan, Yasin, Zuccato, Jeffrey, Moraes, Fabio, Cabanero, Michael, Shali, Wumairehan, Weiss, Jessica, Tsao, Ming, Aldape, Kenneth, Shepherd, Frances, Zadeh, Gelareh
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Biomarkers
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650414/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.002
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi